The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists

This is a generated summary. It shows the 8 most-liked posts from a topic of 54, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
C
chromatogramTL4Analytical chemist4 Jul 2025#3
NLoughran, post #1: Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl J Med , 2024) and finding the comparison harder than it looks. Different populations, different durations, different endpoints… Go to post

This follows post #2 rather than contradicting it.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

21 likes in reply to #1 13mo
EM
e.mensaTL2 Moderator6 Jul 2025#16

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

26 likes 13mo
B
BBramleyTL3Regular7 Jul 2025#19
taper_table, post #13: Worth separating two things that post #9 runs together. Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years. Go to post

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

20 likes in reply to #13 13mo
W
WendelboeTL2Member7 Jul 2025#21

This follows post #18 rather than contradicting it.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

28 likes 13mo
CD
cohort_driftTL3Regular9 Jul 2025#36
l.chevalier, post #15: The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense. Go to post

post #35 answers the question as asked. The question underneath it is different.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

30 likes in reply to #15 13mo
FF
f.fonsecaTL2 Moderator10 Jul 2025 · edited#40
NLoughran, post #29: Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS. Go to post

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

22 likes in reply to #29 13mo
PT
p.trevinoTL2 Moderator10 Jul 2025#44

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

22 likes 13mo
NS
ni.stanescuTL2 Moderator11 Jul 2025#52

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

21 likes 13mo

Read the full topic (54 posts)

Moved from Oral incretins by hana.sato. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

TopicParticipantsRepliesViewsActivity
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…
SRBIHIPINO+128 142 38k 13mo
Why cagrilintide alone is discussed so much less than in combination
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
MENVRFCHKB+93 108 35k 16mo
About the Cagrilintide & amylin analogues category
Long-acting amylin analogues alone and in combination. Mechanism, published data, and the open questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
KBNVBTVPO 4 1.8k 11mo
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of a claim I…
KDPOARNSJH 4 41k 12mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it
On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please…
NSOBGRARBD+2 6 2.4k 7mo

Related topics — sharing the tags effect size, cagrilintide, cagrisema

TopicParticipantsRepliesViewsActivity
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SELECT ( N…
VKJBFNAITH 4 1.3k 1mo
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med ,…
APSKIAOOCV+89 101 32k 8mo
What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited in support…
AAZLHE 2 6.6k 10h
Blinding yourself: practical methods and their limits
On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 4 ( JAMA , 2021) and finding the…
AZMBCRJNC+40 44 33k 5d
Run-in periods and the population they select
On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
DOEVABANLG+130 142 7.3k 1mo